RAPID DOSE THERAPEUTICS INC.

INTERIM MD&A

FOR THE NINE MONTHS ENDED NOVEMBER 30, 2018

DATE: January 29, 2019

The following is the Interim Management's Discussion and Analysis ("**MD&A**") of the business activities including the financial condition and results of operations of Rapid Dose Therapeutics Inc. ("**RDT**" or the "**Company**") for the nine months ended November 30, 2018 prepared as at January 29, 2019. This MD&A should be read in conjunction with the condensed consolidated unaudited interim financial statements for the nine months ended November 30, 2018 and the notes thereto which were prepared in accordance with IAS 34 – Interim Financial Reporting (the "**Financial Statements**").

The Company prepares its financial statements in accordance with the International Financial Reporting Standards ("**IFRS**") as issued by the International Accounting Standards Board. All dollar figures included herein and in the following discussion and analysis are quoted in Canadian dollars unless otherwise stated.

The financial information in this MD&A is derived from the Company's Financial Statements prepared in accordance with IFRS. The reader should also consult the Company's audited annual consolidated financial statements for the period from incorporation on May 3, 2017 to February 28, 2018 and the notes thereto and the condensed consolidated unaudited interim financial statements for the nine months ended November 30, 2018 and the notes thereto, which have been prepared in accordance with IFRS.

This MD&A may contain forward-looking statements based on assumptions and judgments of management regarding events or results that may prove to be inaccurate as a result of events and risk factors beyond its control. Actual results may differ materially from the expected results.

FORWARD-LOOKING STATEMENTS

This MD&A may include certain "forward-looking statements" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical facts, included in this MD&A that address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's businesses, operations, plans and other such matters, are forward-looking statements. When used in this MD&A, the words "estimate", "plan", "anticipate", "expect", ''intend'', "believe" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

DESCRIPTION OF THE BUSINESS, RECENT COMPANY EVENTS

Business -

The Company was incorporated as CTC Pharma International Inc. ("**CTC Pharma**") under the *Business Corporations Act* (British Columbia) on May 3, 2017. On September 11, 2017, CTC Pharma changed its name to Rapid Dose Therapeutics Inc. The Company was founded with the intention of developing and acquiring assets which could be used to deliver active ingredients and over-the-counter products for medicinal, health and recreational applications.

Rapid Dose Therapeutics Inc. ("RDT") is a private Canadian bio-technology corporation which provides proprietary enhanced drug delivery technologies designed to improve patient outcomes. RDT owns a proprietary oral fast-dissolving drug delivery system, QuickStrip™, which is capable of rapidly releasing into the blood stream a list of pharmaceuticals, emulsified oils and over-the-counter medicines without being degraded or modified by first pass metabolism in the liver. RDT also provides product innovation, production and consultation to the pharmaceutical and healthcare manufacturing industry.

RDT continues to execute on its strategy to enter the nutraceutical/over-the-counter sector initially through the completion of distribution agreements for the rights to sell nutraceuticals and over-the-counter products under RDT's brand name QuickStrip™ by distributors.

There is a worldwide market for RDT's QuickStrip™ nutraceutical and OTC products. RDT is sourcing distribution in other countries in order to take advantage of the production capabilities RDT has acquired through its nutraceutical co-packing supply agreement. The U.S. market provides a significant second opportunity with its large complement of national retailers.

Recent Company Events -

On May 29, 2017, RDT entered into an asset purchase agreement ("**APA**") with CTT Pharmaceuticals, Holdings, Inc. ("**CTT**") to acquire CTT's patents, technology and processes for an oral fast-dissolving drug delivery system. The APA was terminated on October 31, 2017 as a result of CTT being unable to satisfy RDT's due diligence requirements and RDT being unable to obtain sufficient comfort with respect to the representations of CTT.

On September 11, 2017, the Company changed its name to Rapid Dose Therapeutics Inc., to more effectively communicate its business purpose and move its business name away from CTC.

On November 15, 2017, the Company entered into a distribution agreement with HED International Inc. ("**HED**"). HED is an equipment manufacturer located in Ringoes, New Jersey, USA, which has provided the Company with the exclusive right to supply HED's oral dissolvable thin-film production equipment to the Canadian cannabis sector. The Company may also supply HED's oral dissolvable thin-film production equipment to other sectors in Canada and to other markets but does not have any exclusive rights in those other sectors or markets.

On January 17, 2018, the Company incorporated a subsidiary, RDT Therapeutics Inc., in the State of Delaware to own and manage its operations in the United States.

On January 26, 2018, the Company engaged Market One Media Group Inc. to provide public and media public relations campaign and content services across a broad spectrum of business and social networks. The services to be provided over a one-year term.

Effective March 1, 2018, the Company entered into a research support agreement with the McMaster University Chemistry Faculty to provide academic research support for RDT's technical testing of the materials, processes and the chemistry of oral dissolvable thin films.

The Company signed an agreement with University of Nevada Las Vegas ("**UNLV**") related to RDT's QuickStrip™ products. Under the scope of the research, the Company will provide UNLV with QuickStrip™ products for exclusive specialized testing to determine the comparative benefits between other dosage forms such as oral and injected of the same active pharmaceutical ingredients on the behavior, bioavailability, and brain waves of subjects. Under the agreement, a team of researchers will conduct comparative studies using established protocols to evaluate whether the QuickStrip™ delivery system improves the rapidity and functionality of therapeutics compared to standard routes of administration. The RDT/UNLV project will assess QuickStrip™ delivery on absorption, distribution, metabolism, electroencephalography and behavioral outcomes.

During the nine-months ended November 30, 2018, the Company issued 3,210,000 common shares for gross proceeds of $1,605,000. Each common share was issued at a price of $0.50 per share. The Company paid cash finders' fees of $115,100 in relation to this private placement.
During the same period, the Company issued 100,000 common shares in exchange for services provided in the amount of $50,000.

During the month of August, the Company also issued 7,200,000 common shares at $0.75 per share for gross proceeds of $5,400,000.

As of February 28, 2018, the Company had 54,331,200 common shares and 840,000 warrants issued and outstanding. As of the end of the period ended May 31, 2018, the Company had 55,961,200 common shares and 840,000 warrants issued and outstanding. As of the end of the period ended August 31, 2018, the Company had 64,841,200 common shares and 840,000 warrants issued and outstanding.

The Company and its subsidiary have recently signed five managed strip services agreements for the Canadian, USA and International markets. See "*Events after the Reporting Date and Commitments*" below.

The Company has recently introduced some QuickStrip™ products in the Canadian nutraceuticals market, following which the Company and its subsidiary have initiated sales in the U.S. market. See "*Events after the Reporting Date and Commitments*" below.

On October 11, 2018, RDT's United States subsidiary, RDT Therapeutics Inc. ("**RDT-US**"), signed a five-year, renewable Managed Strip Services Agreement with Chemesis International Inc. ("**Chemesis**"), a licensed producer and manufacturer of medicinal and recreational cannabis in California. Pursuant to the agreement, Chemesis was granted a license to use RDT's "QuickStrip™" trademarks and other intellectual property in connection with cannabis products produced by Chemesis at its manufacturing facility in Cathedral City, California and sold within the state of California. Under the terms of the Managed Strip Services Agreement, RDT-US will provide Chemesis with production equipment to be operated by Chemesis in California and licensing rights to RDT's technologies and RDT-US will also provide periodic deliveries of certain proprietary formulations and other supplies to enable Chemesis to produce, distribute and sell its cannabis products in California using RDT's QuickStrip™ product delivery method. Under the terms of the agreement, Chemesis is required to hold and maintain all necessary governmental authorizations, permits, licenses, orders, qualifications and other requirements of federal, state and

municipal laws and other regulatory requirements and to operate in compliance with them. Chemesis will pay RDT-US certain service fees – both lump-sum initiating fees and periodic fees based on sales of Chemesis's products produced by Chemesis using RDT's QuickStrip™ product delivery technology.

On October 18, 2018, RDT-US also signed a Managed Strip Services Agreement with Chemesis for products to be sold in the territory of Puerto Rico on terms similar to the terms of its Managed Strip Services Agreement with Chemesis for the state of California.

On October 31, 2018, the Company signed a Sublease Agreement for 34,721 square feet of warehouse and office space at their current location. Lease payment commenced on January 1, 2019 and expire on March 31, 2024. Total minimum lease payments under the operating lease are $2,552,514. The old lease for the office space used expired on December 31, 2018.

On November 1, 2018, RDT signed a five-year, renewable Managed Strip Services Agreement with Aphria Inc. ("**Aphria**"), a leading global cannabis company headquartered in Leamington, Ontario. Pursuant to the agreement, Aphria was granted preferred rights to produce, distribute and sell QuickStrip™ products for the cannabis markets in Canada using QuickStrip™ trademarks and technology. Under the agreement, Aphria will have the ability to extend the agreement to enable it to bring products developed using RDT's QuickStrip™ technology to international markets where Aphria operates currently and in the future. Under the terms of the Managed Strip Services Agreement, RDT will provide Aphria with production equipment to be operated by Aphria in Canada and licensing rights to RDT's technologies and RDT will also provide periodic deliveries of certain proprietary formulations and other supplies to enable Aphria to produce, distribute and sell its cannabis products using RDT's QuickStrip™ product delivery method. Under the terms of the agreement, Aphria is required to hold and maintain all necessary governmental authorizations, permits, licenses, orders, qualifications and other requirements of federal, provincial, state and municipal laws and other regulatory requirements and to operate in compliance with them. Aphria will pay RDT certain service fees – both lump-sum initiating fees and periodic fees based on sales of Aphria's products produced by Aphria using RDT's QuickStrip™ product delivery technology.

On December 7, 2018, the Company completed an amalgamation with ACME Resources Corp. Pursuant to an Amended and Restated Amalgamation Agreement, ACME:

a) issued 64,841,200 common shares to acquire all of the issued and outstanding common shares of the Company on the basis of an exchange ratio of one common share of ACME for each outstanding common share of the Company; and

b) issued 840,000 warrants to replace each of the outstanding warrants of the Company on the basis that the holder will be entitled to acquire one common share of the ACME on the same terms and conditions as the outstanding warrants of the Company.

c) On completion of the amalgamation, ACME also issued a total of 4,907,937 common share to an arm's length party in payment of corporate finance services fees.

Upon completion of the amalgamation and the issuance of the shares to the arm length's party, ACME had 75,021,327 common shares issued and outstanding, of which, 7% were held by ACME shareholders, and approximately 86% were held by the former shareholders of the Company. ACME also has 840,000 warrants issued and outstanding.

Following the closing of the amalgamation, the Company was a wholly-owned subsidiary of ACME and ACME changed its name to Rapid Dose Therapeutics Corp.

On December 17, 2018, RDT also signed a Managed Strip Services Agreement with Aphria Inc. for products to be sold in the territory of Germany on terms similar to the terms of its Managed Strip Services Agreement with Aphria for Leamington, Ontario, Canada.

On January 10, 2019, RDT also signed a Managed Strip Services Agreement with Flower One for products to be sold in the territory of Nevada on terms similar to the terms of other signed Managed Strip Services Agreements.

The Company has initiated its marketing strategy for nutraceuticals by outsourcing the production of certain selected natural healthcare products (including QuickStrip™ B12, QuickStrip™ Energy and QuickStrip™ Melatonin) under the QuickStrip™ brand using QuickStrip™ thin-film strips as a product delivery method. These selected natural healthcare products have received all necessary approvals from Health Canada (including packaging, labelling and NPNs). Production has recently commenced in a certified facility. Although a few initial sales have been completed in Canada and in the United States, there is no assurance that the market for RDT's QuickStrip™ natural healthcare products will grow into any substantial volumes or become profitable.

OVERALL PERFORMANCE AND DISCUSSION OF OPERATIONS

This MD&A is the third interim MD&A prepared by the Company following its first fiscal year since incorporation on May 3, 2017 to February 28, 2018. The Company's financial results for the third quarter of the 2nd year of operations can only be compared to the financial year-end results contained in the Company's audited annual financial statements and the financial results for the period from incorporation to November 30, 2018. Interim financial statements were not prepared by the Company during its first financial year.

As of November 30, 2018, the Company had a cash balance of $4,365,963 compared to $326,267 at February 28, 2018. The increase in cash was a result of private placement financings producing gross proceeds of $7,005,000. As of November 30, 2018, the Company had other current assets of $533,125 compared to $229,595 at the prior year-end of February 28, 2018. The increase was principally from increases in prepaid expenses and HST receivables in relation to the Company's efforts to continue to develop its business, as well as employee advances. Similarly, accounts payable and accrued liabilities at the end of the third quarter ended November 30, 2018 were $199,850 compared to $139,830 at the prior year-end of February 28, 2018, as a result of the payment of accounts payable from the increase in available cash resulting from the Company's private placement financings.

For the period March 1, 2018 to November 30, 2018, the Company reported a net loss of $1,808,764 compared to a net loss of $(578,444) for the period from incorporation to November 30, 2017. The operating expenses comprised of wages and benefits of $562,963 (nil as at November 30, 2017), consulting fees of $372,744 ($444,717 as at November 30, 2017), research and development of $196,544 ($37,342 as at November 30, 2017), marketing and business development of $109,068 ($18,698 as at November 30, 2017), office and administration of $159,426 ($34,999 as at November 30, 2017), professional fees of $182,450 ($37,283 as at November 30, 2017), depreciation of $90,720 ($Nil as at November 30, 2017), rent and TMI of $48,884 ($nil as at November 30, 2017), travel $44,446 ($5,406 as at November 30, 2017), and insurance of $37,540 ($Nil as at November 30, 2017) and patents and trademark of $6,126 ($nil as at November 30, 2017. The foregoing costs incurred by the Company primarily relate to starting up operations and increasing development of the Company's business. Consulting fees were high for the period as a result of management's effort to obtain financing and to document, secure and move toward completion of its proposed business combination transaction with ACME.

SUMMARY OF INTERIM RESULTS

The following financial data, which has been prepared in accordance with IFRS, is derived from the Company's Financial Statements:

	Q1 2018 $	Q2 2018 $	Q3 2018 $	Q4 2018 $	Q1 2019 $	Q2 2019 $	Q3 2019 $
	(Note)						
Revenue	–	–	–	–	–	–	2,206
Loss							
- Total	–	(167,401)	(411,043)	(923,418)	(298,519)	(504,327)	(1,005,918)
- Per share	–	(0.01)	(0.01)	(0.02)	–	(0.01)	(0.02)

Note: Results from the date of incorporation on May 3, 2017 to May 31, 2017

LIQUIDITY

During the period ended November 30, 2018 and to the date of this MD&A, the Company has generated modest revenues from operations. The Company has been financed to date through equity financing and it expects that it will continue to do so and will be able to continue to do so in the future until it generates cash flows from operations.

As of November 30, 2018, the Company had cash of $4,365,963 and other current assets of $533,125 to settle current accounts payable and accrued liabilities of $199,850. The Company's cash position is sufficient to meet short-term obligations. The Company may require additional funds to complete its currently anticipated business development plans. The Company is relying on both product sales and has the option to receive private placements for additional funding.

The Company did not have any commitments for capital expenditures. However, the Company anticipates making capital expenditures from time to time to acquire equipment to fulfill its obligations under managed strip services agreements which the Company has recently entered into and which the Company anticipates entering into as the Company's business develops. The Company believes that it currently has sufficient cash to meet its anticipated capital expenditures in the near term.

CAPITAL RESOURCES

Capital is comprised of the Company's shareholders' equity and any debt that it may issue. As at November 30, 2018, the Company's shareholders' equity includes a deficit of $3,310,626. As at that date, the Company had a cash balance of $4,365,963. The Company's objectives when managing capital are to maintain financial strength and to protect its ability to meet its on-going liabilities, to develop its business, to continue as a going concern, to maintain creditworthiness and to maximize returns for shareholders over the long term.

The Company's sole source of capital has been from the issuance of common shares and warrants.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements as at November 30, 2018 or as of the date of this MD&A.

TRANSACTIONS WITH RELATED PARTIES

Related parties include members of the Board of Directors, key management personnel and any companies controlled by these individuals. Key management personnel include those persons having authority and responsibility for planning, directing and controlling activities of the Company.

Key management for the Company consists of the CEO, CFO, SVP of Business Development. During the period ended November 30, 2018 key management compensation for the nine-month period ended November 30, 2018 was $449,513 (period ended November 30, 2017 - $nil). These consulting fees were paid out in cash.

At the period ended November 30, 2018, a balance of $12,919 was owed to the Company by a key management member for employee advances.

FINANCIAL INSTRUMENTS

Financial instruments include cash and accounts payable and accrued liabilities. The estimated fair value of these financial instruments approximates their carrying values because of the short term to maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from financial instruments. In regard to liquidity risk, the Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due.

With respect to capital risk management, the Company's objective when managing capital is to safeguard the entity's ability to continue as a going concern, so that it can continue to develop its business in order to provide returns for shareholders and benefits for other stakeholders.

The Company sets the amount of cash portion to risk and manages the capital structure and makes adjustments to it in light of current economic conditions and the risk characteristics of the underlying assets, as well as with consideration of externally imposed capital requirements. In order to maintain or adjust the capital structure, the Company may issue new shares, or sell assets to reduce debt.

CRITICAL ACCOUNTING ESTIMATES

The financial statements have been prepared in accordance with IFRS and form the basis for the following discussion and analysis of critical accounting policies and estimates. The Company makes estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities during the course of preparing these financial statements.

Management has made a number of significant estimates and valuation assumptions, including valuation of warrants, going concern assumption, deferred income tax recognition and disclosures of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions are based on present conditions and management's planned course of action as well as assumptions about future business and

economic conditions. Should the underlying estimates change, the recorded amounts could change by a material amount.

For a detailed summary of the Company's significant accounting policies, see Note 3 of the Notes to the Audited Annual Financial Statements from date of incorporation of May 3, 2017 to February 28, 2018.

ACCOUNTING AND REPORTING CHANGES

Effective for annual periods beginning on or after January 28, 2019

IFRS 9, Financial Instruments – Classification and Measurement, is a new standard on financial instruments that will replace IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 addresses classification and measurement of financial assets and financial liabilities as well as derecognition of financial instruments. IFRS 9 has two measurement categories for financial assets: amortized cost and fair value. All equity instruments are measured at fair value. A debt instrument is at amortized cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest. Otherwise it is at fair value through profit or loss.

In May 2014, the IASB issued IFRS 15, which supersedes IAS 11, *Construction Contracts*; IAS 16 *Revenue;* IFRIC 13, *Customer Loyalty Programmes;* IFRIC 15 *Agreements for Construction of Real Estate;* IFRIC 18, *Transfers of Assets from Customers;* and SIC 31, *Revenue-Barter Transactions Involving Advertising* Services. IFRS 15 establishes a single five-step model framework for determining the nature amount, timing and uncertainty of revenue and cash flows arising from a contract with a customer. The standard is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted.

In January 2016, the IASB issued IFRS 16, which requires Lessees to recognize assets and liabilities for most leases. Application of the standard is mandatory for annual reporting period beginning on or after January 1, 2019, with earlier application permitted provided that new revenue standard, IFRS 15 has been applied or is at the same date as IFRS 16.

The Company has not early adopted these revised standards and none of these standards are expected to have a material effect on the financial statements.

RISKS AND UNCERTAINTIES

The Company is exposed to risks of varying degrees of significance which could affect its ability to achieve its strategic objective. The main objectives of the Company's risk management processes are to ensure that the risks are properly identified and that the capital base is adequate in relation to those risks. The principal risks to which the Company is exposed are described below:

a) Credit Risk Management

Credit risk is the risk that a client or vendor will be unable to pay or receive any amounts owed by

or owing to the Company. Management's assessment of the Company's credit risk is low as it is primarily attributable to funds held in Canadian banks, sales tax recoverable from the federal government of Canada, where taxes are included in amounts receivable and amounts receivable from a shareholder of the Company.

b) Liquidity Risk

Liquidity risk is the risk that the Company is not able to meet its financial obligations as they fall due. There can be no assurance that the Company will be able to obtain adequate financing in the future or that the terms of such financing will be favorable. Any equity offering will result in dilution to the ownership interests of the Company's shareholders and may result in dilution to the value of such interest. The Company intends on fulfilling its obligations.

As of November 30, 2018, the Company had cash of $4,365,963 and other current assets of $533,125 to settle current accounts payable and accrued liabilities of $199,850.

c) Market Risk

Market risk incorporates a range of risks. Movements in risk factors, such as market price risk and currency risk, affect the fair values of financial assets and liabilities. The Company is exposed to these risks as they affect the ability of the Company to develop or market its products and the future profitability of the Company.

d) Price Risk

The Company is exposed to price risk with respect to market prices of the products and manufacturing inputs.

e) Interest Rate Risk

The Company has cash balances and no interest-bearing debt. The Company's current policy is to deposit excess cash in interest-bearing accounts at its banking institutions.

Based on management's knowledge and experience of the financial markets, the Company believes that the movements in interest rates that are reasonably possible over the next twelve-month period will not have a significant impact on the Company. The fair value of cash, accounts receivable, employee advances, accounts payable and accrued liabilities approximate carrying value due to the relatively short-term maturities of these instruments.

f) Regulatory Risk and Changes in Laws

The QuickStrip™ medical delivery device requires the approval of Health Canada under *The Access to Cannabis for Medical Purposes Regulations* ("**ACMPR**") to enable RDT's Canadian Licensed Producer customers the right to sell cannabis oil as a QuickStrip™. There is no assurance, at this time, that an application by RDT's customers will result in an approval of the oral thin film strip as an allowable delivery device under present ACMPR regulations. Future amendments to the ACMPR governing the production and distribution of cannabis edibles in Canada will create an additional

opportunity for the approval of the QuickStrip™ as an allowable delivery device. There is presently no fixed timeline as to when amendments to the ACMPR will occur. RDT believes the QuickStrip™ device has consumer benefits and the required scientific data supporting the process used by Health Canada for approving the oral thin film strip.

RDT's cannabis grower customers are subject to a variety of laws, regulations and guidelines relating to the manufacture of cannabis and cannabis-related products as well as laws and regulations relating to health and safety, the conduct of operations and the protection of the environment.

Changes to such laws, regulations and guidelines due to matters beyond the control of the Company may cause adverse effects to the Company's Canadian operations with its Canadian licensed cannabis producer customers.

Any forward-looking information in this MD&A is based on the conclusions of management. The Company cautions that due to risks and uncertainties, actual events may differ materially from current expectations. With respect to the Company's operations, actual events may differ from current expectations due to economic conditions, new opportunities, changing budget priorities of the Company and other factors.

OTHER MATTERS

Legal proceedings

There are no material pending legal proceedings or regulatory actions to which the Company is, or, to the knowledge of management of the Company, is likely to be, a party with the exception of a Statement of Claim issued in the Ontario Superior Court of Justice by CTT and served on the Company on or about September 27, 2018, alleging that the Company used confidential information provided by CTT relating to oral thin film technology, breached obligations of confidence and interfered with CTT's economic interests (the "CTT Claim"). The CTT Claim seeks an interim and a permanent injunction restraining the Company from using or disclosing confidential information and from selling its QuickStrip™ or any other oral thin film wafer of medicine. CTT is also seeking damages in excess of $50,000, an accounting and other relief. The Company believes that the claim is without merit and is not material. The Company has filed a Statement of Defense and intends to defend itself vigorously against claims made by CTT.

Contingent liabilities

At the date of MD&A, management was unaware of any outstanding contingent liability relating to the Company's activities.

Disclosure Controls and Procedures

The Chief Executive Officer (the "**CEO**") and Chief Financial Officer ("**CFO**") are responsible for designing internal controls over financial reporting in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with IFRS. The design of the Company's internal control over financial reporting was assessed as of the date of this MD&A.

Business Risks

The Company has a limited history of operations and has not yet achieved any significant amounts of revenue-producing operations. External financing, primarily through the issuance of common shares, may be required to fund the Company's activities. There can be no assurance that the Company will be able to obtain adequate financing. Investment in securities of the Company should be considered a speculative investment. The following risk factors should be given special consideration when evaluating an investment in any of the Company's Securities:

Dilution: There are 840,000 outstanding to which common shares of the Company may be issued in the future. This will result in further dilution to the Company's shareholders.

Revenues and Dividends: The Company has started to recognize some revenues from its nutraceutical division and anticipates revenues in the foreseeable future from its managed strip services division. In the event that the Company generates any meaningful revenues in the future, then the Company intends to retain its earnings in order to finance further growth. Furthermore, the Company has not paid any dividends in the past and does not expect to pay any dividends in the future.

OUTLOOK

RDT is continuing to commercialize its intellectual property and brand 'Quickstrip', as we complete our production facility at our head office and negotiate new agreements.

We are also entering the animal health category in 2019 and continuing to expand our reach into the Americas and Europe. Our nutraceutical lines will expand as five more products will be available in North America by the end of 2020.

Our continued research and development will lead to additional patents being filed and new revenue options being created for the Company by 2020.

APPROVAL

The Board of Directors of the Company approved the disclosures contained in this MD&A on January 29, 2019.

DIRECTORS AND OFFICERS

Mark Upsdell, *President, Chief Executive Officer and Director*
Jason Lewis, *Senior Vice-President of Business Development and Director*
Brian Howlett, *Director*
Ken Fox, *Director*
Lino A. Fera, *Chief Financial Officer*

DISCLOSURE OF OUTSTANDING SECURITIES

	November 30, 2018	**January 29, 2019**
Common shares	64,841,200	75,121,327
Share purchase and finder's warrants	840,000	740,000

Stock options	Nil	Nil
Fully Diluted	65,681,200	75,861,327